A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease

Overview of attention for article published in Neurology, July 2011

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (98th percentile)
High Attention Score compared to outputs of the same age and source (96th percentile)

Mentioned by

news: 5 news outlets
policy: 2 policy sources
twitter: 14 X users

patent: 3 patents
f1000: 1 research highlight platform
guideline: 1 clinical guideline source

Readers on

mendeley: 282 Mendeley
connotea: 1 Connotea

So far, Altmetric has seen 15 X posts from 14 X users, with an upper bound of 148,762 followers.

RT @SnupSnus: @caloriesproper2 Ah found it that was easy-here's the Simvastatin trial 18 months N~400: https://t.co/Ie1XfbSdII So seems to…

@caloriesproper2 Ah found it that was easy-here's the Simvastatin trial 18 months N~400: https://t.co/Ie1XfbSdII So seems to me eighter we are mislead by confounders in the epi/observational data or there is a hitherto undefined subgroup that might bene…

https://t.co/r72EVobkhT https://t.co/2EPAIyirV7 https://t.co/E5RYfmYVPK

Are ApoE4 carriers indeed 40% more likely to delay cognitive decline if they take a statin? The catch here: cognitive baseline between groups was different. Hence, we require a proper prospective RCT. Wait! https://t.co/W6VSIieb1b Then another statin? …

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 11 additional X posts.